The report is lacking in comments. So we have to read the numbers.
RFT mostly manufacturers goods to order. Meaning little risk of unsold inventory.
The gross margin on sales was close to 50%(revenue $39.4m and cost of sales $20.4m).
Inventory has ballooned by $12.6m to $18.4m.
If this was to follow the same margin as in FY23, then one can assume that if most of that will go into goods sold, then RFT has just about $36.8m of goods/stock to sell in the near future(it can't really be calculated like this, but just illustrating that inventory if managed properly would translate in a large amount of sales)
FY22 end had inventory "only" $5.8m and sales in FY23 were $39m. To me with the above it looks like sales into FY24 (at least the first half) will be very strong also, but you have to do your own guesswork and make up your own mind about this.
- Forums
- ASX - By Stock
- RFT
- Ann: Preliminary Final Report
Ann: Preliminary Final Report, page-64
-
- There are more pages in this discussion • 91 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RFT (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.7¢ |
Change
-0.001(12.5%) |
Mkt cap ! $9.673M |
Open | High | Low | Value | Volume |
0.7¢ | 0.7¢ | 0.7¢ | $478 | 68.28K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
22 | 2264428 | 0.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.8¢ | 387893 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
22 | 2264428 | 0.007 |
11 | 2142492 | 0.006 |
9 | 2566843 | 0.005 |
4 | 3175000 | 0.004 |
3 | 1900000 | 0.003 |
Price($) | Vol. | No. |
---|---|---|
0.008 | 387893 | 3 |
0.009 | 5434998 | 4 |
0.010 | 1162493 | 5 |
0.011 | 692914 | 1 |
0.012 | 2415355 | 7 |
Last trade - 14.34pm 10/10/2024 (20 minute delay) ? |
Featured News
RFT (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, MD & CEO
James Graham
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online